Literature DB >> 28325990

Perceptions of Hepatotoxicity in Medical Therapies.

Naga P Chalasani1.   

Abstract

Entities:  

Year:  2006        PMID： 28325990      PMCID： PMC5358083     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Authors:  Masanori Ikeda; Ken-ichi Abe; Masashi Yamada; Hiromichi Dansako; Kazuhito Naka; Nobuyuki Kato
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

2.  Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.

Authors:  Naga Chalasani; Evgenia Teal; Stephen D Hall
Journal:  Am J Gastroenterol       Date:  2005-06       Impact factor: 10.864

3.  Incidence of statin hepatotoxicity in patients with hepatitis C.

Authors:  Shirin Khorashadi; Noelle K Hasson; Ramsey C Cheung
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-11       Impact factor: 11.382

4.  An assessment of statin safety by hepatologists.

Authors:  David E Cohen; Frank A Anania; Naga Chalasani
Journal:  Am J Cardiol       Date:  2006-02-03       Impact factor: 2.778

5.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

6.  Second-generation thiazolidinediones and hepatotoxicity.

Authors:  Todd R Marcy; Mark L Britton; Steve M Blevins
Journal:  Ann Pharmacother       Date:  2004-07-20       Impact factor: 3.154
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.